A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)
Martha E. Teke(National Institutes of Health), Kim A. Reiss(University of Pennsylvania), Areeba Saif(National Institutes of Health), Jonathan M. Hernandez(National Institutes of Health), Stephanie C. Lux(National Institutes of Health), Carrie E. Ryan(University at Buffalo, State University of New York)
Cited by 6
Related Papers
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
|JAMA Oncology|2019|289
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>
|Journal of Clinical Oncology|2021|238
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
|British Journal of Cancer|2019|206
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
|Nature Medicine|2025|189